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Abstract
Triptolide is a potent natural product, with documented antiproliferative, immunosuppressive,
anti-inflammatory, antifertility, and anti-polycystic kidney disease effects. Despite a wealth of
knowledge about the biology of this compound, direct intracellular target proteins have remained
elusive. We synthesized a biotinylated photoaffinity derivative of triptolide, and used it to identify
dCTP pyrophosphatase 1 (DCTPP1) as a triptolide-interacting protein. Free triptolide interacts
directly with recombinant DCTPP1, and inhibits the enzymatic activity of this protein. Triptolide
is thus the first dCTP pyrophosphatase inhibitor identified, and DCTPP1 is a biophysically
validated target of triptolide.
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Introduction
A panoply of functions have been ascribed to the natural product triptolide (1).[1] This
compound is the major bioactive constituent of Tripterygium wilfordii Hook F., also known
as the Thunder God Vine or lei gong teng, a traditional Chinese medicine that is a rich
source of secondary metabolites.[2] A decoction of the vine has a variety of uses in the
traditional Chinese pharmacopoeia, including treatment of arthritis, inflammation and
autoimmune disorders.[3] Little wonder, then, that triptolide has anti-inflammatory and
immunosuppressive functions, but it also has potent antiproliferative and anti-fertility
activity. Pure triptolide has shown preclinical efficacy in various models of arthritis, organ
transplantation, graft-versus-host disease, and cancer.[4]
Despite this large body of work describing triptolide’s organismal and cellular effects, its
molecular functions remain to be fully delineated. Using radiolabeled triptolide and
extensive cellular fractionation, our group previously identified polycystin-2 as a triptolide-
associating protein.[5] Polycystin-2 is a Ca2+ channel encoded by PKD2, one of two
causative genes for autosomal dominant polycystic kidney disease (PKD); this finding is
consistent with evidence that some of triptolide’s cellular effects are Ca2+ dependent.[6]
When either polycystin-2 or its obligate activator polycystin-1 (PKD1) is mutated, growth-
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arresting Ca2+ influx in the developing kidney tubule is blocked. This is thought to lead to
the disease phenotype of enlarged kidneys ultimately rendered non-functional by fluid-filled
cysts. Intriguingly, triptolide can stimulate polycystin-2 channel opening in the absence of
polycystin-1,[5] suggesting that it could have therapeutic use in the 85% of PKD patients
with a PKD1 mutation. Indeed, this is the case in mouse models in which Pkd1 is lost
constitutively,[5] neonatally,[7] or post-natally.[8]
Triptolide also functionally interacts with the general transcription apparatus, decreasing
expression of a huge variety of genes.[9] This effect was originally ascribed to NF-κB
pathway inhibition, but has recently been attributed to a direct effect on RNA polymerases
(RNAPs) (reviewed in [10]). Our group showed that triptolide decreases phosphorylation of
Ser2 of the C-terminal domain of RNAP II, leading to decreased RNAP II-mediated
transcription and cessation of mRNA splicing, as indicated by nuclear speckle rounding.[11]
Subsequent to this, triptolide causes nucleolar disassembly and RNAP I blockade. These
findings are consistent with an earlier report of general transcriptional blockade by
triptolide,[12] and recent indications that triptolide shuts down total RNA production.[9]
Triptolide can induce degradation of RPB1, the catalytic subunit of RNAP II.[9] While the
current manuscript was under revision, it was reported that triptolide can covalently interact
with and inhibit the general transcription factor TFIIH component XPB, explaining its
transcriptional effects.[13]
Remarkably, prior to the identification of XPB as a triptolide target,[13] no direct interaction
had been observed between triptolide and RNAP II components, nor indeed with
polycystin-2. Others, however, have identified proteins that seem to interact with triptolide.
McCallum et al.[14] found that [3H]-triptolide can bind irreversibly to a 90 kDa protein in the
nuclear fraction of A549 and THP-1 cells; to our knowledge, this protein has not been
conclusively identified. More recently, Soundararajan et al.[15] used an affinity
chromatography approach to identify the transmembrane metalloprotease ADAM10 as a
triptolide interactor in U937 cells. Triptolide treatment decreased the expression of full-
length ADAM10, but increased the levels of a putative non-catalytic fragment of this
cancer-associated protein, and synergized with the cytotoxic effect of ADAM10
knockdown.
These intriguing studies point to important functions of triptolide, but to date, no direct
interacting proteins have been biophysically confirmed. Here, we use a novel triptolide
photoaffinity reagent 2 to identify dCTP pyrophosphatase 1 (DCTPP1, formerly known as
XTP3TPA) as a direct interactor with triptolide. The DCTPP1 enzyme has not previously
been characterized in humans, although the mouse ortholog (RS21-C6) was identified as an
ITP-binding protein[16] and a member of the MazG NTP pyrophosphatase family.[17] The
ubiquitously expressed, Mg2+-dependent,[16] cytoplasmic murine enzyme is an α-helical-
rich homotetramer[18] that has maximal hydrolytic activity against 5-halo-dCTP analogs, but
can also remove pyrophosphate from 5-methyl-dCTP and dCTP.[16] It has been speculated
that DCTPP1 may regulate the balance between dCTP and dTTP by hydrolyzing the former
to dCMP, which is converted to dUMP by dCMP deaminase, and then to dTMP by
thymidylate synthase.[16] Alternatively, DCTPP1 may remove genotoxic halo-dCTP analogs
from the nucleotide pool.[16] We show here that the human enzyme has similar catalytic
activity to the murine form, and that triptolide is the first known inhibitor of this enzyme.
Results
A photoaffinity pulldown approach to find triptolide targets
We synthesized compound 2, linking triptolide to benzophenone and biotin (Scheme 1), and
used this compound or control compound 3 lacking the triptolide moiety to detect proteins
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that interact specifically with the triptolide photoaffinity reagent in HeLa S3 cell lysates. In
the S100 (soluble protein) fraction, four robust bands were observed after UV crosslinking
in the presence of 2 that were not pulled down by 3 (Figure 1A). Moreover, one of these
bands was covalently biotinylated, as indicated by streptavidin-HRP reactivity (Figure 1B).
Binding of these bands to the affinity reagent could be competed with excess triptolide, and
interestingly, these bands were still pulled down without UV crosslinking, indicating a
strong interaction (Figure 1A). However, in the absence of UV crosslinking, the band was
not biotinylated, indicating that the triptolide-protein interaction is noncovalent. Peptide
mass fingerprinting identified all four bands as DCTPP1.
Confirmation of DCTPP1 as the photoaffinity reagent target
Immunoblot with an anti-DCTPP1 antibody confirmed that all four bands seen on silver
staining were indeed DCTPP1 (Figure 1C). Treatment of the pulldown reaction with β-
mercaptoethanol prior to electrophoresis caused these four bands to collapse into a single,
approximately 18 kDa band, the correct size for monomeric DCTPP1. One of the higher
molecular weight bands represents dimeric DCTPP1, consistent with the “dimer of dimers”
proposed structure of the mouse ortholog of this enzyme.[18] The conformers or post-
translational modifications that lead to the other bands remain unknown.
To confirm that DCTPP1 was the direct target of the affinity reagent, and not a member of a
complex pulled down by the reagent, we expressed 6His-DCTPP1 in E. coli. This
recombinant protein could be efficiently pulled down with 2, but not with linker control
compound 3 (Figure 1D), indicating an interaction between 2 and DCTPP1 that does not
rely on other eukaryotic accessory proteins.
Biophysical and enzymatic characterization of the triptolide-DCTPP1 interaction
Although we had shown that “free” triptolide could compete DCTPP1 from 2, we wanted to
confirm a direct interaction between triptolide 1 and the protein. We purified bacterially
expressed GST-DCTPP1 and cleaved off the GST tag, yielding recombinant DCTPP1
(Figure 2). The recombinant protein existed primarily as a dimer (Supplementary Figure
S1). By ITC, this protein interacted with 1 with KD = 44 ± 4 μM, ΔH = −19.98 ± 1.70 kcal/
mol, n = 0.601 ± 0.075 (Figure 2), suggesting that a single molecule of triptolide binds to
each dimer of DCTPP1. Titration of 1 into buffer alone and of buffer into DCTPP1 did not
generate any appreciable response in this assay (Figure 2), indicating the specificity of the
observed interaction.
Since DCTPP1 is an enzyme, we investigated whether 1 can inhibit its activity. Using a
kinetic, luminescent assay that detects pyrophosphate generation, we first established that, as
with the murine enzyme, 5-I-dCTP is a good substrate for DCTPP1 (KM = 239 μM, kcat =
8.64×10−4 s−1, kcat/KM = 3.5 s−1·M−1). We then showed that 1 inhibits DCTPP1 activity,
with kinetics suggestive of a non-competitive mechanism (Table 1; Supplementary Figure
S2). Several close triptolide analogs also inhibited this enzyme with broadly similar efficacy
(Table 1). None of these compounds inhibited the luminescent assay itself (data not shown).
Importance of DCTPP1 for triptolide-induced cytotoxicity
Given triptolide’s biochemical effects on DCTPP1, we next tested whether DCTPP1 is an in
vivo triptolide target. To determine if DCTPP1 is important for triptolide’s cytotoxic effects,
we overexpressed DCTPP1 or knocked it down by siRNA in HeLa cells (Figure 3A).
Neither treatment had a perceptible effect on proliferation or cell morphology (data not
shown). Moreover, neither treatment changed the cells’ response to triptolide (Figure 3B,
C).
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Effect of DCTPP1 on BrdC incorporation into DNA
Since one proposed function of DCTPP1 is the removal of potentially toxic, base modified
nucleosides from the pool of DNA precursors,[16] we took advantage of a readily available
anti-BrdU antibody to investigate this function. BrdC is converted in the cell to BrdCTP,
which in turn is converted to BrdUTP before incorporation into DNA as BrdU.[19] We
confirmed that treatment of HeLa cells with both BrdC and BrdCTP gave detectable BrdU
incorporation of 30–43% of cells after a one-hour treatment, similar to that seen for BrdU
treatment. However, neither knockdown nor overexpression of DCTPP1 significantly
modified the fraction of anti-BrdU reactive cells (data not shown).
Effect of DCTPP1 on cytidine nucleoside analog-induced cytotoxicity
Since chemotherapeutic cytidine nucleoside analogs cytarabine and gemcitabine must be
incorporated into DNA to exert their replication-blocking effects, and since only nucleoside
triphosphates are capable of entering DNA synthesis, we asked whether DCTPP1 might
function in detoxifying these compounds by maintaining them in the monophosphate state.
However, knockdown or overexpression of DCTPP1 did not have any effect on the
cytotoxicity of these compounds in HeLa cells, and gemcitabine triphosphate[20] did not
show activity as a DCTPP1 substrate in kinetic assays (data not shown).
Discussion
The identification of relevant molecular targets of the potent natural product triptolide 1
remains a challenge. Here, we have identified DCTPP1 as the first known, biophysically
validated, direct protein interactor with triptolide. Triptolide interacts strongly, but non-
covalently with DCTPP1 (Figure 1), consistent with our previous work[6] suggesting that 1
need not bind covalently in the cell (although others have suggested that it can[13-14]). By
exogenous expression of DCTPP1 in E. coli, we showed that our triptolide photoaffinity
reagent binds directly to this enzyme; this finding was borne out by ITC, indicating a direct
interaction between the protein and natural product (Figure 2). Moreover, 1 and closely
related compounds 4–7 inhibit the pyrophosphatase activity of DCTPP1 (Table 1).
Triptolide is the first known inhibitor of this enzyme, and one of a very small group of
nucleotide pyrophosphatase inhibitors that are not nucleotide analogs. It will be interesting
to see if 1 inhibits any other MazG proteins, or more distantly related pyrophosphatases.
Triptolide and similar compounds will therefore be of interest to those working on the
enzymology and functional relevance of DCTPP1.
However, DCTPP1 is unlikely to be the key physiological target of 1. The compound binds
and inhibits recombinant DCTPP1 at concentrations substantially higher than those
necessary for biological effects, and modulation of DCTPP1 expression did not change the
cytotoxicity of 1 (Figure 3). In addition, the majority of [3H]-triptolide associates with
membrane proteins,[6] whereas DCTPP1 is a cytoplasmic enzyme seen in the S100 fraction
in our experiments. Of course, endogenous DCTPP1 might be inhibited by lower
concentrations of the compound than the recombinant enzyme used here in vitro, and
inhibition of DCTPP1 might be responsible for some of triptolide’s effects other than
cytotoxicity; this possibility remains to be investigated.
We have cloned and expressed for the first time human DCTPP1, which appears to behave
similarly to the orthologous murine enzyme in terms of substrate preference for 5-halo-
dCTPs (TWC, unpublished data). However, our recombinant DCTPP1 does not seem to
require obligate tetramerization for function, although transient or weak tetramerization
cannot be ruled out (Supplementary Figure S1). We investigated whether DCTPP1 is
involved in the metabolism of the chemotherapeutic cytidine nucleoside analogs cytarabine
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and gemcitabine. Modulation of DCTPP1 expression did not affect the cytotoxicity of these
agents, nor did gemcitabine triphosphate serve as a substrate for the recombinant enzyme
(data not shown). These results suggest that DCTPP1 is not involved in resistance to these
drugs. It remains to be seen if DCTPP1 might act to dephosphorylate the triphosphates of
antiretroviral cytidine nucleoside analogs, such as zalcitabine (dideoxycytidine), lamivudine
(2′,3′-dideoxy-3′-thiacytidine), or emtricitabine (2′-deoxy-5-fluoro-3′-thiacytidine). If
such an activity exists, it might suggest a role in inter-individual efficacy of these drugs,
based on variations in DCTPP1 expression. DCTPP1 has been postulated to act as a
“gatekeeper” enzyme, ensuring that potentially deleterious halogenated nucleotides do not
enter DNA synthesis.[16] We tested this hypothesis by monitoring the incorporation of BrdC
and BrdCTP into DNA using anti-BrdU antibodies (data not shown). Since we saw no
differential incorporation with decreased or increased DCTPP1 expression, it seems unlikely
that this enzyme functions to block brominated dCTP from incorporation into the genome,
although DCTPP1 might have this function for 5-I-dCTP or other variants in vivo.
In summary, we have shown that the natural product triptolide inhibits DCTPP1, and
examined the function of this human enzyme for the first time. This finding is a significant
step toward resolving fully the mechanism of triptolide’s action and provides an important
new tool for the further study of DCTPP1.
Experimental Section
Chemical synthesis
Full details of chemical syntheses and characterization data are available in the Supporting
Information. Briefly, synthesis of 2 began with 3, synthesized as described,[21] which was
then coupled to triptolide-succinate (obtained from direct reaction of 1 with succinic
anhydride), to give the final triptolide-photoaffinity reagent 2. 14-α-triptolide 7 was
obtained by borohydride reduction of triptonide 4 (Sequoia Research Products),[22] while 5-
hydroxytriptonide 6 was produced by selenium dioxide oxidation of 4.
Photoaffinity pulldown
Neutravidin-agarose (Thermo) was washed three times with isotonic lysis buffer (25 mM
Tris pH 7.4, 150 mM NaCl, Complete Protease Inhibitors (Roche), 1 mM sodium
orthovanadate, 1 mM sodium pyrophosphate, 10 mM β-glycerophosphate) and blocked 1
hour with cytochrome c (1 mg/mL). After washing, beads were exposed overnight to affinity
reagent 2 or control 3 (100 μM, diluted from 10 mM DMSO stocks). To bind free avidin
sites, biotin (1 mM) was added for 1 hour.
A frozen pellet of 5 L equivalent HeLa S3 cells (National Cell Culture Center/Biovest
International) was thawed, suspended in isotonic lysis buffer (7.5 mL), and lysed with 25
strokes of a Dounce homogenizer. After a 2 minute centrifugation at 2000 g to remove
nuclei and unlysed cells, the supernatant was ultracentrifuged at 100,000 g for 45 minutes.
The resulting S100 (soluble protein) fraction was split in four, and appropriate beads were
added. For the triptolide competition condition, 1 (1 mM) (Pi & Pi Technology) was added
15 minutes prior to bead addition. After rotation for 1 hour at 4°C, beads were collected,
resuspended in isotonic lysis buffer + 1% Triton X-100 in 3 cm tissue culture plates, and
exposed to UV (or not) for 30 minutes at 4°C, using a homemade exposure chamber
consisting of two desk lamps each fitted with two F15T8/BLB 15W blacklight bulbs,
emitting 1.2 mJ·cm−2·s−1 of 366 nm light at sample distance. Beads were then washed with
the same buffer into microfuge tubes and washed twice more, followed by two washes in a
similar buffer containing 350 mM NaCl and a final wash in a salt-free buffer. Beads were
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boiled 10 minutes in 2× NuPAGE sample buffer (Invitrogen) (with or without 5% β-
mercaptoethanol) prior to separation on 12% Bis-Tris acrylamide gels.
Proteins were detected by silver staining, as follows. SDS-PAGE gels were fixed in 50%
methanol-10% acetic acid (2×20 minutes), then washed in 20% ethanol (10 minutes) and
water (10 minutes). Gels were reduced in 0.02% sodium thiosulfate solution (1 minute),
washed with water (2×20 s), then exposed to 0.2% silver nitrate (30 minutes, 37°C). After a
brief wash with water, gels were incubated in developing solution (3% Na2CO3·H2O, 0.05%
formaldehyde, 0.001% sodium thiosulfate). Stop solution was 1% acetic acid. Stained gels
were imaged with a ChemiDoc XRS+ (BioRad) and QuantityOne software. Trypsinization
and LC/MS/MS peptide mass fingerprinting were performed by Midwest Bio Services, with
identification using SEQUEST software.
Immunoblotting
DCTPP1 was detected by immunoblot of pulldown experiments or RIPA lysates of
transfected cells. Briefly, proteins on SDS-PAGE or native tris-glycine gels were
electrotransferred to nitrocellulose membranes (75 V, 90 minutes) and membranes were
blocked with 5% BSA (pulldowns) or 5% BLOTTO (cell lysates) in TBST. To detect
biotinylated proteins, membranes were incubated with streptavidin-HRP (Thermo), 1:1000
in TBST. To detect DCTPP1, anti-DCTPP1 (Atlas Antibodies or Santa Cruz) was used
1:500 in BLOTTO/TBST, followed by anti-rabbit-HRP (GE). β-actin was detected with a
monoclonal antibody (Sigma) at 1:10,000 in TBST followed by anti-mouse-HRP (GE). ECL
+ (GE) chemiluminescence was detected by film exposure or with a ChemiDoc XRS+
(BioRad).
Molecular biology
The 510 bp ORF of human DCTPP1 was PCR amplified from a spleen cDNA library
(Proquest) using primers adding a 5′ Bam HI site and a 3′ Pac I s i t e : A A G G A T C C C
A T G T C T G T G G C C G G T G G G G A and
CTTTAATTAACTAGGTTGAGGTCTGGCCTGTGG, respectively. The PCR product was
cloned into a modified pRSF-1b vector[23] using these sites, to yield pRSF-1b-6His-
DCTPP1. DCTPP1 was subcloned into eukaryotic expression vector pCS2+ by
amplification from this construct using the same forward primer, and a reverse primer
introducing a C-terminal HA tag and an Eco RI restriction site:
TAGAATTCTAGGCATAGTCTGGGACGTCATATGGATAGGTTGAGGTCTGGCCTG
TG G. Similarly, DCTPP1 was subcloned from pRSF-1b-6His-DCTPP1 into pGEX-2T
using a frameshifted forward primer introducing a Bam HI site, and a reverse primer
introducing an Eco RI site: AAGGATCCATGTCTGTGGCCGGTGGGGA and
ttGAATTCTAGGTTGAGGTCTGGCCTGTGG, respectively. All vectors were confirmed
by sequencing.
6His-DCTPP1 Pulldown from E. coli
E. coli BL21 Star (DE3) (Invitrogen) transformed with pRSF-1b-6His-DCTPP1 was grown
from a single colony overnight at 37°C, diluted 10-fold into LB+kanamycin (250 mL), then
induced overnight at room temperature with IPTG (0.5 mM), pelleted and frozen at –80°C.
Thawed cells were sonicated 3×20s in PBS + EDTA-free Complete Protease Inhibitors
(Roche), then centrifuged at 13,000 g for 10 minutes. The supernatant was filtered through
0.45 μm mesh, then added to Neutravidin beads bound with 2 or 3 as above. Pulldown,
wash, and immunoblot conditions were as described above.
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Recombinant DCTPP1 expression & purification
E. coli BL21 Star (DE3) (Invitrogen) transformed with pGEX-2T-DCTPP1 was grown from
a single colony overnight at 37°C in LB+carbenicillin (200 mL), then diluted 10-fold into 2
L and induced for 4 hours at 37°C with IPTG (1 mM), then pelleted and frozen at –80°C.
Thawed cells were sonicated 4×30s in PBS, then centrifuged at 13,000 g for 10 minutes. The
supernatant was filtered through 0.45 μm mesh, then bound to glutathione-sepharose (GE)
for 30 minutes. The beads were washed five times with PBS, then protein eluted with 50
mM Tris-HCl pH 8.0, 10 mM reduced glutathione. Thrombin (GE, 30 units) was added and
incubated overnight at 4°C, then buffer was exchanged for Tris-HCl (50 mM) over a PD-10
(GE) column. To remove thrombin and GST, the resulting preparation was separated over a
0-1000 mM KCl gradient on a MonoQ HR 5/5 column (GE) using an ÄKTAExplorer 100
FPLC system controlled by Unicorn 5.2 software (GE). The most intense DCTPP1 peak
eluted at 600 mM KCl. This and surrounding fractions were combined and dialyzed twice
against 20 mM Tris, pH 7.4 using 6000-8000 MWCO tubing (Spectrum), concentrated over
a 10,000 MWCO spin column (Amicon), then stored at 4°C. Recombinant protein
concentration was determined by Bradford assay (Bio-Rad) read on a Wallac Victor 2 plate
reader. Multimerization was confirmed by native Tris-glycine 10% PAGE and size
exclusion chromatography over a calibrated Superdex 75 10/300 GL column with isocratic
20 mM Tris, pH 7.5, 50 mM NaCl.
ITC
ITC experiments were performed on an iTC200 instrument (MicroCal) at 25°C, 1000 rpm
stirring. DCTPP1 was diluted in post-dialysis Tris buffer to 50 μM monomer concentration
and 2% DMSO. Triptolide was dissolved in minimal DMSO, and brought to a final
concentration of 1.5 mM in the same Tris buffer, with final 2% DMSO. Triptolide was
injected into DCTPP1 over 39 injections, initial: 0.5 μL, 1 s, 60 s space between injections;
then 0.75 μL, 1.5 s, 120 s space between injections. Control experiments were similar, but
with 60 s between all injections. Data were analyzed and binding curves fitted using Origin
7 software. Parameters are expressed as values ± SD.
Enzyme kinetic analyses
Kinetic enzyme assays were performed in 384-well, white plates (Nunc) on a Wallac Victor
2 plate reader. Each 20 μL reaction contained assay buffer (50 mM Tris, pH 8.0, 100 mM
KCl, 5 mM MgCl2, 100 μg/mL BSA, 1 mM DTT),[15] PPiLight reagent (10 μL) (Lonza),
DCTPP1 (125 nM), substrate (at 10, 30, 100, or 300 μM), and inhibitor (at 0, 0.2, 2, 20, 200,
or 500 μM in 1 μL DMSO). Substrates in H2O were: 5-I-dCTP (TriLink) and gemcitabine
triphosphate (NSC746306 from the NCI/DTP Open Chemical Repository, http://
dtp.cancer.gov).[20] Inhibitors in DMSO were triptolide 1 (Pi & Pi Technologies), triptonide
4 and triptriolide 5 (also known as both triol-triptolide and epi-triptolide; Sequoia Research
Products), 5-hydroxytriptonide 6, and 14-α-triptolide 7. Octuplicate wells were set up for
each condition and the plate pre-warmed at 37°C; prewarmed enzyme and PPiLight reagent
master mix was added to start the reaction, which was monitored by 80 reads of
luminescence detection, with 122 s between reads of the same well. A sodium
pyrophosphate standard curve in quadruplicate was included in all assays. The data points in
the linear range of each condition (typically 244 to 732 s) were converted to μM
pyrophosphate using the equivalent points on the standard curve, then linear regression was
used to find the slope, v0. Prism 5.0 (GraphPad) was used for enzyme kinetic analyses to
determine KM, kcat, and Ki using non-competitive kinetics. Parameters are expressed as
values ± SE.
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DCTPP1 overexpression and knockdown effect on cytotoxicity
For DCTPP1 overexpression, HeLa cells grown in 12-well plates in DMEM with 10% FBS
and penicillin-streptomycin were transfected with pCS2+-DCTPP1-HA or empty vector
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. For
knockdown, similar cells were transfected with siRNA (4 pmol) targeting DCTPP1
(SASI_Hs01_00014964) or a negative control (Mission siRNA Universal Negative Control
#1, Sigma) using Lipofectamine RNAiMAX (Invitrogen). One day after transfection,
transfected cells were trypsinized and added to 384-well, white tissue culture plates (750
cells/well in 25 μL). Octuplicate wells (overexpression) or quintuplicate wells (knockdown)
were exposed to the indicated concentrations of triptolide in DMSO (0.4% final), or
gemcitabine or cytarabine in H2O for 48 hours, then proliferation was determined by
CellTiterGlo (Promega) luminescence on a Wallac Victor 2 Plate Reader. Data were
analyzed and IC50 values calculated using Prism 5.0. All experiments were performed at
least twice.
BrdC incorporation
HeLa cells transfected with DCTPP1-HA or siRNA as above were trypsinized and plated on
poly-L-lysine-coated coverslips at a density of 100,000 cells per well of a 12-well plate. The
next day, cells were treated with BrdC (10 μM) (NSC61765 from the NCI/DTP Open
Chemical Repository, http://dtp.cancer.gov) or BrdCTP (TriLink) in growth medium for 30
minutes, then washed with PBS and fixed in 70% ethanol in 50 mM glycine-HCl, pH 2.0, 20
minutes at –20°C. After PBS washes, anti-BrdU antibody was applied according to the
instructions for the BrdU Labeling and Detection Kit II (Roche), 30 minutes at 37°C. After
PBS washes, goat anti-mouse-Alexa 594 conjugate (Invitrogen) was added at 1:500 in PBS,
30 minutes, 37°C. Following final PBS washes, slides were mounted in Vectashield (Vector
Labs), and imaged with a Camedia C3040ZOOM camera mounted on a CK40 inverted
microscope (Olympus). All experiments were performed twice.
Supplementary Material
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Identification of DCTPP1 as a triptolide target. (A) silver stained gel and (B) streptavidin-
HRP blot of soluble protein lysates of HeLa S3 cells exposed to the reagents indicated:
triptolide affinity reagent 2, affinity reagent 2 + 100-fold excess of “free” triptolide 1,
affinity reagent 2 without UV exposure, and control compound 3 lacking triptolide moiety.
Triptolide affinity reagent-specific bands of approximately 40, 37, 22, and 18 kDa are
evident; the 22 kDa band is biotinylated. (C) anti-DCTPP1 immunoblot. All four bands
visible in (A) are detected with the anti-DCTPP1 antibody in the affinity reagent lane; no
bands are evident in the triptolide competition lane. Addition of β-mercaptoethanol (β-ME)
prior to electrophoresis causes all four bands to collapse into a single, 18 kDa band. (D)
6His-DCTPP1, as detected by anti-DCTPP1 immunoblot, can be specifically pulled down
from a crude E. coli lysate using the triptolide affinity reagent 2, but not the control
compound 3.
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Triptolide binds DCTPP1. (A) Partially purified DCTPP1. Coomassie-stained PAGE shows
dimer, denatured by β-mercaptoethanol (+β-ME), monomer and cleaved GST. (B)
Isothermal titration calorimetry shows that triptolide binds DCTPP1 with KD = 44 ± 4 μM,ΔH = –19.98 ± 1.70 kcal/mol, n = 0.601 ± 0.075. Integrated heats for the indicated
experiments are shown.
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Modulation of intracellular DCTPP1 does not modify triptolide-induced cytotoxicity. (A)
DCTPP1-HA overexpression (OE) and siRNA-mediated knockdown (KD) of the
overexpressed protein, quantified relative to negative control (Neg) siRNA transfection and
normalized to β-actin levels. (B) Dose-response of cell number (measured by CellTiterGlo
luminescence in arbitrary units, AU) after 48 hours’ exposure to the indicated triptolide
concentration, in HeLa cells transiently transfected with DCTPP1-HA (OE) or vector
(pCS2+) control; or (C) transfected with a negative control siRNA (Neg) or an siRNA
targeting DCTPP1 (KD). IC50 = 7–10 nM.
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Compounds used in this study. Triptolide (1), triptolide photoaffinity reagent consisting of
triptolide linked to benzophenone linked to biotin (2), control photoaffinity reagent (3),
triptonide (4), triptriolide (5), 5-hydroxytriptonide (6), and 14-α-triptolide (7).
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Table 1
Kinetic data for inhibition of human DCTPP1 by triptolide and analogs. Substrate in all cases was 5-I-dCTP.
Inhibitor Ki ± SE (μm)
Triptolide 1 168 ± 17
Triptonide 4 135 ± 20
Triptriolide 5 85 ± 7
5-hydroxytriptonide 6 356 ± 96
14-α-triptolide 7 194 ± 28
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